The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat

@article{Zagni2017TheSF,
  title={The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat},
  author={Chiara Zagni and Giuseppe Floresta and G. Monciino and A. Rescifina},
  journal={Medicinal Research Reviews},
  year={2017},
  volume={37}
}
Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression. In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases. Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T‐cell lymphoma. This review provides… Expand
View on Wiley
ncbi.nlm.nih.gov
47 Citations
Highly Influential Citations
1
Background Citations
17
Methods Citations
1

47 Citations

Citation Type

Citation Type

Chimeric HDAC inhibitors: Comprehensive review on the HDAC‐based strategies developed to combat cancer
  • 40
Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
  • 1
The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker
  • 5
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
  • PDF
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
  • PDF
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
  • 12
Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer
  • 1
Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
  • 10
Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy.
  • 14
Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent
  • 1
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 205 REFERENCES
Selective class IIa HDAC inhibitors: myth or reality
  • 27
Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
  • 130
Emerging approaches for histone deacetylase inhibitor drug discovery
  • 53
Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
  • 304
Design of novel histone deacetylase inhibitors.
  • 41
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
  • 433
  • PDF
Inside HDACs with more selective HDAC inhibitors.
  • 118
Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
  • 7
Anticancer activities of histone deacetylase inhibitors
  • 2,544
  • PDF
Histone deacetylase inhibitors: a review on class-I specific inhibition.
  • 15
...
1
2
3
4
5
...